Reuters logo
BRIEF-RedHill Biopharma reveals phase IIa results of RHB-104
December 12, 2016 / 2:13 PM / a year ago

BRIEF-RedHill Biopharma reveals phase IIa results of RHB-104

Dec 12 (Reuters) - RedHill Biopharma Ltd

* RedHill Biopharma announces phase IIa 48-week final results further supporting potential of RHB-104 in multiple sclerosis

* RedHill Biopharma - top-line final (48 weeks) results are consistent with previously announced interim results

* RedHill Biopharma -“top-line final results from patients who completed 48-week study period demonstrated marked improvement over historical self-control”

* RedHill Biopharma - overall, RHB-104 was well-tolerated

* Redhill Biopharma - RHB-104 appeared safe, well-tolerated, with no drug-related serious adverse events/ clinically relevant/ unexpected adverse events Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below